This month’s roundup of new hires, investment funding, partnerships, and other industry news includes key firms such as Clinical Ink, Medable, CPhI, and Sterling Pharma.
LabCorp acquires South Bend Medical Foundation’s diagnostic clinical laboratory testing business, which pathology and blood banking services to patients in Indiana, Michigan, Ohio, and Illinois.
To meet the needs of increasingly complex clinical trials, and sponsor desire for control and scalability, Covance launches an expanded FSP offering focused on delivering ‘clean data.’
Novogene is working with Mission Bio to offer customers in China access to the Tapestri Platform, which is being used in the drug development process by LabCorp and more than a dozen institutions.
Newly-minted Signant Health named a new CTO, Parexel bolstered its Japan presence, and BioAgilytix’s CEO was appointed to the board of FSD Pharma – a company developing products based on cannabinoids – among other people on the move in June.
Two US Attorney Generals have opened an investigation into the data breach at AMCA that compromised a combined nearly 20 million patients at LabCorp and Quest Diagnostics – as the companies’ efforts to notify the public are called into question.
LabCorp participated in a $3m Series B2 financing round for Kiyatec, which is developing ex vivo 3D cell culture technology to help model and predict cancer patients’ response to drug therapies.
LabCorp’s Covance Drug Development segment is set to acquire Envigo’s nonclinical research services business for $485m – while Envigo will purchase Covance’s research products business.
LabCorp’s collaboration with Mission Bio will use single cell-sequencing technology to understand the genetics of rare cell populations, which could be key to making clinical trials successful, says CEO.
LabCorp has launched Pixel by LabCorp, a consumer-initiated wellness test offering that allows for sample self-collection and access to online results.
LabCorp sees significant opportunity to grow its Covance Drug Development business in the face of a potentially challenging 2019 and is on track to deliver costs savings as part of its LaunchPad initiatives.
LabCorp signed several partnership deals in the second quarter of 2018 as the company aims to enhance the drug development process and continues to invest in its CRO business.
